Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 May 2021
Congress loves a big pharma villain. But will that lead to any real policy changes on drug prices?
21 May 2021 - There's a funny cycle that resurfaces every now and then within the life sciences industry. ...
Posted by Michael Wonder on 23 May 2021
COVID-19 vaccine rollout: Aussies could get COVID-19 jabs by Christmas
23 May 2021 - The federal government has made a major change to the Pfizer rollout, and it could see Australians ...
Posted by Michael Wonder on 22 May 2021
US biotech Novavax could make COVID vaccine onshore in Australia
20 May 2021 - American biotechnology company Novavax has outlined plans to make doses of its coronavirus vaccine in Australia ...
Posted by Michael Wonder on 21 May 2021
Health insurers ‘sit on pot of gold’, say private hospitals
21 May 2021 - Private hospitals say health insurers must promise to reduce premium hikes or pay cash back to ...
Posted by Michael Wonder on 21 May 2021
EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19
21 May 2021 - EMA’s CHMP has completed its review on the use of the monoclonal antibody sotrovimab (also known as ...
Posted by Michael Wonder on 21 May 2021
Vaxzevria: further advice on blood clots and low blood platelets
21 May 2021 - EMA has provided additional advice on blood clots or low blood platelets occurring after vaccination with Vaxzevria ...
Posted by Michael Wonder on 21 May 2021
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
21 May 2021 - Today, the FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen), a bispecific antibody directed against epidermal ...
Posted by Michael Wonder on 21 May 2021
U.S. FDA grants priority review of maribavir for the treatment of post-transplant recipients with cytomegalovirus infection in those resistant and/or refractory to prior anti-CMV treatment
21 May 2021 - New drug application based on Phase 3 trial of maribavir which met its primary outcome of superiority ...
Posted by Michael Wonder on 21 May 2021
New listings for opioid medications on the Palliative Care Schedule for the management of severe disabling pain from 1 June 2021
21 May 2021 - Commencing 1 June 2021, the Palliative Care Schedule will include new and amended listings for opioid ...
Posted by Michael Wonder on 21 May 2021
Biosimilar bevacizumab on the PBS - information for health professionals and patients
21 May 2021 - A biosimilar brand of bevacizumab (Mvasi) will be listed on the PBS on 1 June 2021. Information ...
Posted by Michael Wonder on 21 May 2021
TGA evaluating first monoclonal antibody treatment for COVID-19 sotrovimab - GlaxoSmithKline
21 May 2021 - The Therapeutic Goods Administration granted a provisional determination to GlaxoSmithKline in relation to the monoclonal antibody ...
Posted by Michael Wonder on 21 May 2021
PHARMAC to work with others to improve communication
21 May 2021 - PHARMAC accepts the Coroner’s comments that not all information about the brand change reached patients. ...
Posted by Michael Wonder on 20 May 2021
Government calls for pitches for mRNA vaccine production facilities
21 May 2021 - Plans to build a new Australian vaccine facility will be launched on Friday in a call ...
Posted by Michael Wonder on 20 May 2021
Thousands of AstraZeneca shots pile up in federal-run clinics as GPs wait
20 May 2021 - Thousands of AstraZeneca doses are sitting unused in federal government-run clinic refrigerators across Sydney and regional ...
Posted by Michael Wonder on 20 May 2021
Omeros announces extension of FDA review period for narsoplimab in HSCT-TMA
20 May 2021 - PDUFA date is 17 October 2021. ...